All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
Introducing
Now you can personalise
your GvHD Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe GvHD Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the GvHD Hub cannot guarantee the accuracy of translated content. The GvHD Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
Plasmacytoid dendritic cells (pDC) in donor grafts showed increased survival and reduced graft-versus-host disease (GvHD) in recipients of bone marrow (BM), but not in recipients receiving granulocyte-colony stimulating factor peripheral blood grafts.
Mojibade Hassan from Emory University, Atlanta, GA, presented results of a study examining FMS-like receptor tyrosine kinase 3 ligand (Flt3L) treated BM (F-BM) and pDC’s effect on transplant outcomes in a murine transplant model at the 44th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) in Lisbon, Portugal.
Hassan concluded her talk by stating that Flt3L treatment of bone marrow donors significantly increased survival and decreased GvHD. Additionally, F-BM grafts increased survival in a murine tumor model. To conclude, the speaker highlighted that “upregulation of adaptive immune pathways and downregulation of toll-like receptor cascades in Flt3L treated bone marrow grafts may play a role in attenuation of GvHD post transplant.”
Subscribe to get the best content related to GvHD delivered to your inbox